×
About 200 results

ALLMedicine™ Alpha1-antitrypsin Deficiency Center

Research & Reviews  65 results

Characterization of hepatic inflammatory changes in a C57BL/6J mouse model of alpha1-an...
https://doi.org/10.1152/ajpgi.00207.2022
American Journal of Physiology. Gastrointestinal and Live... Khodayari N, Oshins R et. al.

Oct 19th, 2022 - Alpha-1 antitrypsin deficiency (AATD) is a genetic disease caused by a hepatic accumulation of mutant alpha-1 antitrypsin (ZAAT). Individuals with AATD are prone to develop a chronic liver disease that remains undiagnosed until late stage of the d...

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency
https://clinicaltrials.gov/ct2/show/NCT04722887

Aug 16th, 2022 - The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg/kg) and 144 mg/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC) infusion and subsequently as weekly SC infusions over 8 weeks in ...

Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency.
https://doi.org/10.1056/NEJMoa2205416
The New England Journal of Medicine; Strnad P, Mandorfer M et. al.

Jun 25th, 2022 - Alpha1-antitrypsin (AAT) deficiency results from carriage of a homozygous SERPINA1 "Z" mutation (proteinase inhibitor [PI] ZZ). The Z allele produces a mutant AAT protein called Z-AAT, which accumulates in hepatocytes and can lead to progressive l...

Subacute Nodular Migratory Panniculitis (Vilanova Disease)
https://emedicine.medscape.com/article/1081813-print

May 13th, 2022 - Practice Essentials Vilanova disease, or subacute nodular migratory panniculitis, was first observed in 1954[1] and then named by Vilanova and Pinol Aguade in 1956.[2] Vilanova's original 14 patients were all women, most of whom were in their fift...

Subacute Nodular Migratory Panniculitis (Vilanova Disease)
http://emedicine.medscape.com/article/1081813-overview

May 13th, 2022 - Practice Essentials Vilanova disease, or subacute nodular migratory panniculitis, was first observed in 1954 [1] and then named by Vilanova and Pinol Aguade in 1956. [2] Vilanova's original 14 patients were all women, most of whom were in their fi...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  7 results

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency
https://clinicaltrials.gov/ct2/show/NCT04722887

Aug 16th, 2022 - The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg/kg) and 144 mg/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC) infusion and subsequently as weekly SC infusions over 8 weeks in ...

Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency
https://clinicaltrials.gov/ct2/show/NCT02870309

Oct 28th, 2021 - This study is a multicenter, open-label trial to evaluate the safety and pharmacokinetics of weekly intravenous (IV) infusions of 60 mg/kg of the investigational drug in participants with alpha1-antitrypsin deficiency (AATD). The trial will be con...

Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)
https://clinicaltrials.gov/ct2/show/NCT03172455

Oct 5th, 2020 - GLASSIA (human alpha-1 proteinase inhibitor (A1PI), also known as human alpha-1 antitrypsin, Kamada-AAT or Kamada-API) is a, liquid, ready-to-use preparation of human A1PI. Alpha-1 proteinase inhibitor belongs to the family of serine proteinase in...

Liver Disease in Patients With alpha1-antitrypsin Deficiency
https://clinicaltrials.gov/ct2/show/NCT02929940

May 31st, 2017 - Alpha1-antitrypsin deficiency (AAT deficiency) is a frequently overlooked metabolic disorder. Apart from lung disease, AAT deficiency also leads to liver disease. This can affect people of all ages and all ethnic groups. Although involvement of th...

Alpha1-antitrypsin Deficiency Registry
https://clinicaltrials.gov/ct2/show/NCT00005292

Mar 25th, 2016 - BACKGROUND: Severe congenital deficiency for alpha1-antitrypsin is associated with the early onset of emphysema, usually by the third decade of life. One approach to correct this deficiency is though replacement with alpha1-antitrypsin (referred t...

see more →

News  4 results

Older Lung Donors Raise Mortality Risk Only Slightly
https://www.medscape.com/viewarticle/862727

May 2nd, 2016 - WASHINGTON, DC — For people who undergo lung transplantation, mortality risk is only slightly higher when donors are 55 to 64 years of age than when they are younger than 55 years, the current age recommendation, according to an analysis of the wo...

Alpha1-Antitrypsin Deficiency Significantly Increases Risk for Lung Cancer
https://www.staging.medscape.com/viewarticle/575125

May 27th, 2008 - May 27, 2008 — Alpha1-antitrypsin deficiency (AATD) can greatly increase the risk for lung cancer, researchers report. AATD carriers might have a risk of developing lung cancer that is 70% higher than that for noncarriers, according to new data pu...

Alpha1-Antitrypsin Deficiency Significantly Increases Risk for Lung Cancer
https://www.medscape.com/viewarticle/575125

May 27th, 2008 - May 27, 2008 — Alpha1-antitrypsin deficiency (AATD) can greatly increase the risk for lung cancer, researchers report. AATD carriers might have a risk of developing lung cancer that is 70% higher than that for noncarriers, according to new data pu...

Drug reduces mutant protein that can lead to fibrosis in rare genetic liver disease undefined Video Open in new tab Open in new tab Open in new tab Open in new tab Open in new tab Open in new tab O...
https://www.reuters.com/business/healthcare-pharmaceuticals/drug-reduces-mutant-protein-that-can-lead-fibrosis-rare-genetic-liver-disease-2022-06-27/

(Reuters Health) - The experimental Arrowhead Pharmaceuticals drug fazirsiran can reduce the accumulation of a mutant protein by 83% among people with alpha1-antitrypsin deficiency (AAT) disease, according to results from an open-label phase 2 tri...

see more →